Our professionals

Imagen del Dr. José Mª Argemí, hepatólogo de la Clínica Universidad de Navarra

Dr. Josepmaría Argemí

Principal Investigator of the Stress Responses and Liver Cancer Immunotherapy group.
Specialist in Internal Medicine.
Preferential dedication to the study and treatment of liver diseases and tumors of the liver area.

Be part of: Cima Universidad de Navarra Clínica Universidad de Navarra Cancer Center Clínica Universidad de Navarra
INDEX H 20

Professional career

Graduated in Medicine from the University of Barcelona (1997-2003).

Specialist in Internal Medicine from the Università Campus Bio-Medico, Rome, Italy (2005-2010).

Doctor of Medicine, University of Navarra (2010-2015).

Post-doctoral Fellowship at the University of Pittsburgh (2017-2020).

Head of Translational Genomics at the Genomics Unit, CIMA, Universidad de Navarra (2020-2023).

He is currently a Consulting Physician in the Liver Unit of the Department of Internal Medicine of the University of Navarra Clinic, Associate Professor in the Faculty of Medicine of the University of Navarra and an Adjunct Assistant Professor in the Division of Gastroenterology, Hepatology and Nutrition of the University of Pittsburgh (PA, USA).

RESEARCH AREAS

  • Principal Investigator within the DNA and RNA Medicine Division of the Center for Applied Medical Research (CIMA) in the Therapeutic long non-coding RNAs and integrated stress in Cancer group.
  • Associate Researcher of the Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBER-EHD) and of the "Área de Aparato Digestivo y Metabolismo" of the Instituto de Investigación Sanitaria de Navarra (IdisNA). Member of the Cancer Center University of Navarra (CCUN) Scientific Committee.

The basic, translational and clinical research carried out in these years has been focused on the field of liver disease related to alcohol abuse, liver regeneration and the immunotherapy of liver cancer.

Through his research work, he has revealed the role of cellular stress response systems during liver regeneration. Currently he has focused his attention on the mechanisms of cellular stress that lead to immune evasion by cancer cells with a view to developing new strategies to increase the effectiveness of immunotherapy in liver cancer. He is also developing several projects and collaborations in the search for predictive biomarkers of response to immune check-point inhibitors.

AREAS OF INTEREST

  • Study and treatment of liver diseases from initial stages to cirrhosis of the liver.
  • Study and treatment of liver tumors.
  • Study of biomarkers of response to immunotherapy.

Activity

In teaching

  • Associate Professor in the School of Medicine of the University of Navarra.
  • Teaching in the field of physiopathology of the digestive system and in the field of general medical pathology.

In research

  • He has co-edited 1 educational book and has coauthored more than 60 articles in first quartile indexed journals, of which 22 within the first decile and 8 with preferential authorship in high impacted journals. 
  • He has been co-inventor of 2 international patents.
  • He co-directs doctoral theses related to liver cancer.
Imagen de un icono azul con un documento certificado.

Recognition

  • In January 2020 he has been appointed Adjunct Assistant Professor at the University of Pittsburgh (USA), where he continues to make periodic stays to coordinate research projects in genomics applied to hepatology.

Scientific institutions

  • Member of the International Liver Cancer Association (ILCA).
  • Member of the American Association for the Study of Liver Diseases (AASLD).
  • Member of the European Association for the Study of the Liver (EASL).

Latest scientific publications

More information